Eyenovia (NASDAQ:EYEN) is scheduled to be releasing its earnings data before the market opens on Tuesday, November 13th. Analysts expect Eyenovia to post earnings of ($0.42) per share for the quarter.
Eyenovia (NASDAQ:EYEN) last posted its quarterly earnings data on Tuesday, August 14th. The company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.09. On average, analysts expect Eyenovia to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
EYEN stock traded down $0.18 during mid-day trading on Tuesday, reaching $3.65. 200 shares of the stock traded hands, compared to its average volume of 21,845. Eyenovia has a 52-week low of $2.94 and a 52-week high of $10.74. The firm has a market capitalization of $39.19 million and a PE ratio of -1.67.
A number of research firms have commented on EYEN. Zacks Investment Research raised shares of Eyenovia from a “sell” rating to a “hold” rating in a research note on Wednesday, July 25th. HC Wainwright started coverage on shares of Eyenovia in a research note on Tuesday, October 9th. They set a “buy” rating and a $12.00 price objective for the company. Finally, ValuEngine raised shares of Eyenovia from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $18.31.
ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/11/06/eyenovia-eyen-to-release-quarterly-earnings-on-tuesday.html.
Eyenovia, Inc, a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia.
Further Reading: Institutional Investors
Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.